Christopher Cao1,2,3, Daniel Wang4, David H Tian5,6, Ashley Wilson-Smith5, James Huang1, Andreas Rimner7. 1. Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 2. Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia. 3. Chris O'Brien Lifehouse Hospital, Sydney, Australia. 4. Department of Medicine, Cornell University, New York, USA. 5. Collaborative Research Group, Macquarie University, Sydney, Australia. 6. Department of Anaesthesia, Westmead Hospital, Sydney, Australia. 7. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: There is growing evidence to support the hypothesis that radical treatment of pulmonary oligometastatic disease with stereotactic body radiation therapy (SBRT) can improve oncological outcomes. However, some reports suggest colorectal cancer (CRC) pulmonary metastases are associated with radioresistance. The present systematic review aimed to assess the local control (LC), overall survival (OS), and progression-free survival (PFS) of patients with CRC pulmonary metastases treated by SBRT. Secondary outcomes included assessment of peri-procedural complications and identification of prognostic factors on LC. METHODS: Electronic databases were systematically searched from their dates of inception using predefined criteria. Summative statistical analysis was performed for patients with CRC pulmonary metastases, and comparative meta-analysis was performed for patients with CRC versus non-CRC pulmonary metastases. RESULTS: Using predefined criteria, 18 relevant studies were identified from the existing literature. LC for CRC pulmonary metastases treated by SBRT at 1-, 2-, and 3-year were estimated to be 81%, 66%, and 60%, respectively. OS and PFS at 3-year were 52% and 13%, respectively. Patients with CRC pulmonary metastases were associated with significantly lower LC compared to non-CRC pulmonary metastases [HR, 2.93; 95% confidence interval (CI), 1.93-4.45; P<0.00001], but higher OS (HR, 0.61; 95% CI, 0.45-0.82; P=0.001). There were no reported periprocedural mortalities and low incidences of periprocedural morbidities. CONCLUSIONS: These findings may have implications for patient and treatment selection, dose fractionation, and support the hypothesis that CRC pulmonary metastases may require higher biological effective doses while respecting normal tissue constraints when treated with SBRT. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: There is growing evidence to support the hypothesis that radical treatment of pulmonary oligometastatic disease with stereotactic body radiation therapy (SBRT) can improve oncological outcomes. However, some reports suggest colorectal cancer (CRC) pulmonary metastases are associated with radioresistance. The present systematic review aimed to assess the local control (LC), overall survival (OS), and progression-free survival (PFS) of patients with CRC pulmonary metastases treated by SBRT. Secondary outcomes included assessment of peri-procedural complications and identification of prognostic factors on LC. METHODS: Electronic databases were systematically searched from their dates of inception using predefined criteria. Summative statistical analysis was performed for patients with CRC pulmonary metastases, and comparative meta-analysis was performed for patients with CRC versus non-CRC pulmonary metastases. RESULTS: Using predefined criteria, 18 relevant studies were identified from the existing literature. LC for CRC pulmonary metastases treated by SBRT at 1-, 2-, and 3-year were estimated to be 81%, 66%, and 60%, respectively. OS and PFS at 3-year were 52% and 13%, respectively. Patients with CRC pulmonary metastases were associated with significantly lower LC compared to non-CRC pulmonary metastases [HR, 2.93; 95% confidence interval (CI), 1.93-4.45; P<0.00001], but higher OS (HR, 0.61; 95% CI, 0.45-0.82; P=0.001). There were no reported periprocedural mortalities and low incidences of periprocedural morbidities. CONCLUSIONS: These findings may have implications for patient and treatment selection, dose fractionation, and support the hypothesis that CRC pulmonary metastases may require higher biological effective doses while respecting normal tissue constraints when treated with SBRT. 2019 Journal of Thoracic Disease. All rights reserved.
Entities:
Keywords:
Stereotactic body radiation therapy (SBRT); colorectal cancer (CRC); meta-analysis; pulmonary metastasis; systematic review
Authors: Haoming Qiu; Alan W Katz; Amit K Chowdhry; Kenneth Y Usuki; Deepinder P Singh; Su Metcalfe; Praveena Cheruvu; Yuhchyau Chen; Paul Okunieff; Michael T Milano Journal: Am J Clin Oncol Date: 2018-01 Impact factor: 2.339
Authors: Kamran A Ahmed; William J Fulp; Anders E Berglund; Sarah E Hoffe; Thomas J Dilling; Steven A Eschrich; Ravi Shridhar; Javier F Torres-Roca Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-30 Impact factor: 7.038
Authors: Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky Journal: Neurosurg Focus Date: 2017-01 Impact factor: 4.047
Authors: Steven A Eschrich; Jimmy Pramana; Hongling Zhang; Haiyan Zhao; David Boulware; Ji-Hyun Lee; Gregory Bloom; Caio Rocha-Lima; Scott Kelley; Douglas P Calvin; Timothy J Yeatman; Adrian C Begg; Javier F Torres-Roca Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-01 Impact factor: 7.038
Authors: Kyle E Rusthoven; Brian D Kavanagh; Stuart H Burri; Changhu Chen; Higinia Cardenes; Mark A Chidel; Thomas J Pugh; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: Ann Thorac Surg Date: 2020-04-09 Impact factor: 4.330
Authors: Mara Antonoff; Leah Backhus; Daniel J Boffa; Stephen R Broderick; Lisa M Brown; Phillip Carrott; James M Clark; David Cooke; Elizabeth David; Matt Facktor; Farhood Farjah; Eric Grogan; James Isbell; David R Jones; Biniam Kidane; Anthony W Kim; Shaf Keshavjee; Seth Krantz; Natalie Lui; Linda Martin; Robert A Meguid; Shari L Meyerson; Tim Mullett; Heidi Nelson; David D Odell; Joseph D Phillips; Varun Puri; Valerie Rusch; Lawrence Shulman; Thomas K Varghese; Elliot Wakeam; Douglas E Wood Journal: J Thorac Cardiovasc Surg Date: 2020-04-09 Impact factor: 5.209
Authors: Hoon Sik Choi; Bae Kwon Jeong; Ki Mun Kang; Hojin Jeong; Jin Ho Song; In Bong Ha; Oh-Young Kwon Journal: Cancer Res Treat Date: 2020-07-21 Impact factor: 4.679
Authors: Sara Lindberg; Eva Onjukka; Peter Wersäll; Caroline Staff; Rolf Lewensohn; Giuseppe Masucci; Karin Lindberg Journal: Clin Transl Radiat Oncol Date: 2022-07-21
Authors: Raghav Chandra; John D Karalis; Charles Liu; Gilbert Z Murimwa; Josiah Voth Park; Christopher A Heid; Scott I Reznik; Emina Huang; John D Minna; Rolf A Brekken Journal: Cancers (Basel) Date: 2021-12-09 Impact factor: 6.639